Key result
The reduced uterine perfusion pressure model induced cardiac fibrosis and increased FKBPL expression, a finding mirrored in human cardiac spheroids treated with plasma from women with preeclampsia.
Why the study?
Much of the pathogenesis and mechanisms involved in cardiac health in preeclampsia are unknown, and the novel anti-angiogenic protein FKBPL has an emerging potential role in both preeclampsia and cardiovascular disease.
Absolute Event Rate: 1.46% vs 1%
p-value: p=0.018
The RUPP rat model and preeclampsia plasma-treated cardiac spheroids demonstrate increased cardiac FKBPL expression, suggesting a role for this anti-angiogenic protein in the cardiovascular pathogenesis of preeclampsia.
May implicate FKBPL in preeclampsia-associated cardiac fibrosis; hypothesis-generating and leaves open clinical translation.
BACKGROUND: Preeclampsia is a dangerous cardiovascular disorder of pregnancy that leads to an increased risk of future cardiovascular and metabolic disorders. Much of the pathogenesis and mechanisms involved in cardiac health in preeclampsia are unknown. A novel anti-angiogenic protein, FKBPL, is emerging as having a potential role in both preeclampsia and cardiovascular disease (CVD). Therefore, in this study we aimed to characterise cardiac health and FKBPL regulation in the rat reduced uterine perfusion pressure (RUPP) and a 3D cardiac spheroid model of preeclampsia. METHODS: The RUPP model was induced in pregnant rats and histological analysis performed on the heart, kidney, liver and placenta (n ≥ 6). Picrosirius red staining was performed to quantify collagen I and III deposition in rat hearts, placentae and livers as an indicator of fibrosis. RT-qPCR was used to determine changes in Fkbpl, Icam1, Vcam1, Flt1 and Vegfa mRNA in hearts and/or placentae and ELISA to evaluate cardiac brain natriuretic peptide (BNP45) and FKBPL secretion. Immunofluorescent staining was also conducted to analyse the expression of cardiac FKBPL. Cardiac spheroids were generated using human cardiac fibroblasts and human coronary artery endothelial cells and treated with patient plasma from normotensive controls, early-onset preeclampsia (EOPE) and late-onset preeclampsia (LOPE); n = 3. FKBPL and CD31 expression was quantified by immunofluorescent labelling. RESULTS: The RUPP procedure induced significant increases in blood pressure (p < 0.001), collagen deposition (p < 0.001) and cardiac BNP45 (p < 0.05). It also induced a significant increase in cardiac FKBPL mRNA (p < 0.05) and protein expression (p < 0.01). RUPP placentae also exhibited increased collagen deposition and decreased Flt1 mRNA expression (p < 0.05). RUPP kidneys revealed an increase in average glomerular size (p < 0.05). Cardiac spheroids showed a significant increase in FKBPL expression when treated with LOPE plasma (p < 0.05) and a trend towards increased FKBPL expression following treatment with EOPE plasma (p = 0.06). CONCLUSIONS: The rat RUPP model induced cardiac, renal and placental features reflective of preeclampsia. FKBPL was increased in the hearts of RUPP rats and cardiac spheroids treated with plasma from women with preeclampsia, perhaps reflective of restricted angiogenesis and inflammation in this disorder. Elucidation of these novel FKBPL mechanisms in cardiac health in preeclampsia could be key in preventing future CVD.
No takes yet. Share an insight, caveat, or question.
Richards et al. (2021) studied Preeclampsia. Reduced uterine perfusion pressure (RUPP) and preeclamptic plasma vs. Sham surgery and normotensive plasma was evaluated on Cardiac FKBPL protein expression (fold change) (p=0.018). The reduced uterine perfusion pressure model induced cardiac fibrosis and increased FKBPL expression, a finding mirrored in human cardiac spheroids treated with plasma from women with preeclampsia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: